Waddington Simon N, Kramer M Gabriela, Hernandez-Alcoceba Ruben, Buckley Suzanne M K, Themis Michael, Coutelle Charles, Prieto Jesus
Gene Therapy Research Group, Sir Alexander Fleming Building, Imperial College, South Kensington, London SW7 2AZ, UK.
Mol Ther. 2005 May;11(5):661-76. doi: 10.1016/j.ymthe.2005.01.015.
Over the past few years, considerable progress in prenatal diagnosis and surgery combined with improvements in vector design vindicate a reappraisal of the feasibility of in utero gene therapy for serious monogenetic diseases. As adult gene therapy gathers pace, several apparent obstacles to its application as a treatment may be overcome by pre- or early postnatal treatment. This review will examine the concepts and practice of prenatal vector administration. We aim to highlight the advantages of early therapeutic intervention focusing on diseases that could benefit greatly from a prenatal gene therapy approach. We will pay special attention to the strategies and vectors that are most likely to be used for this application and will speculate on their expected developments for the near future.
在过去几年中,产前诊断和手术取得了显著进展,同时载体设计也有所改进,这使得重新评估子宫内基因治疗严重单基因疾病的可行性成为可能。随着成人基因治疗的加速发展,作为一种治疗方法应用时面临的一些明显障碍,可能通过产前或出生后早期治疗得以克服。本综述将探讨产前载体给药的概念和实践。我们旨在强调早期治疗干预的优势,重点关注那些可从产前基因治疗方法中大幅受益的疾病。我们将特别关注最有可能用于此应用的策略和载体,并推测它们在不久的将来的预期发展。